Is this you? Create Your Porfile
Avatar

Y. Fujii

Network

Latest external collaboration on country level. Dive into details by clicking on the dots.

Explore More

Hotspot

Dive into the research topics where Y. Fujii is active.

Explore More

Publication

Featured researches published by Y. Fujii.

European Urology Supplements | 2013

E80 Administration of the selective alpha 1A adrenoceptor antagonist silodosin facilitates expulsion of size 5–10 mm distal ureteral stones, as compared to control

Y. Itoh; A. Okada; K. Taguchi; Y. Hirose; K. Niimi; Y. Fujii; T. Kobayashi; M. Usami; S. Hamamoto; R. Ando; M. Hirose; T. Yasui; K. Tozawa; K. Kohri

Objective nRecently, we reported that alpha 1A-adrenoceptor (AR) is the main participant in phenylephrine-induced human ureteral contraction. We therefore decided to carry out a prospective randomized study to evaluate the effects of silodosin, a selective alpha 1A AR antagonist, as a medical expulsive therapy (MET) for distal ureteral stones.

European Urology Supplements | 2015

395 Hypercalciuria and migration of inflammatory macrophages play key roles for kidney stone formation in metabolic syndrome model mice

R. Unno; K. Taguchi; Y. Fujii; K. Takahiro; S. Hamamoto; R. Ando; A. Okada; T. Itoh; T. Yasui; K. Tozawa; Y. Hayashi; K. Kohri

European Urology Supplements | 2013

E18 Association of the loci 5q35.3, 7q14.3, and 13.q14.1 with urolithiasis in the Japanese population

T. Yasui; A. Okada; M. Usami; Y. Hirose; Y. Ito; K. Taguchi; Y. Fujii; K. Niimi; S. Hamamoto; R. Ando; M. Hirose; Y. Itoh; K. Tozawa; Y. Higashi; Y. Sato; K. Matsuda; K. Kohri

European Urology Supplements | 2013

311 Active phagocytosis and processing of calcium oxalate monohydrate crystals in an in vitro macrophage model

A. Okada; T. Yasui; L. Zuo; K. Taguchi; Y. Fujii; Y. Itoh; Y. Hirose; M. Usami; K. Niimi; R. Ando; T. Kobayashi; S. Hamamoto; M. Hirose; K. Tozawa; K. Kohri

European Urology Supplements | 2013

E88 Macrophage-derived cytokines and chemokines may be novel markers to predict calcium oxalate stone formation in humans

A. Okada; T. Yasui; K. Taguchi; Y. Ito; Y. Hirose; Y. Fujii; K. Niimi; M. Usami; T. Kobayashi; S. Hamamoto; M. Hirose; Y. Itoh; K. Tozawa; K. Kohri

European Urology Supplements | 2012

856 Calcium oxalate crystals could be englobed by macrophages during kidney stone formation in vitro and in vivo models

A. Okada; K. Taguchi; Y. Hirose; K. Niimi; Y. Fujii; T. Kobayashi; M. Usami; S. Hamamoto; M. Hirose; Y. Itoh; T. Yasui; K. Tozawa; K. Kohri

European Urology Supplements | 2012

952 Efficacy of Dornier official technical training for SWL treatment at the university hospital

S. Hamamoto; A. Okada; K. Taguchi; Y. Hirose; K. Niimi; Y. Fujii; R. Ando; T. Kobayashi; M. Usami; M. Hirose; Y. Itoh; T. Yasui; K. Tozawa; K. Kohri

European Urology Supplements | 2012

852 M-CSF is a novel preventive agent against renal stone disease by inducing anti-inflammatory macrophages

K. Taguchi; A. Okada; Y. Fujii; K. Niimi; T. Kobayashi; S. Hamamoto; M. Hirose; Y. Itoh; T. Yasui; K. Tozawa; S. Sasaki; Y. Hayashi; K. Kohri

European Urology Supplements | 2011

E17 Opening of mitochondrial permeability transition pores induces kidney stone formation

K. Niimi; T. Yasui; K. Taguchi; Y. Fujii; Y. Hirose; T. Kobayashi; S. Hamamoto; M. Hirose; A. Okada; Y. Itoh; K. Tozawa; K. Kohri

European Urology Supplements | 2011

712 HYPOTHETICAL NEW ASPECTS OF HUMAN KIDNEY STONE FORMATION; COMPARISON OF CLINICAL AND PATHOLOGICAL FINDINGS OF STONE-FORMING AND NON-STONE-FORMING KIDNEYS

A. Okada; K. Nakaoka; J. Ichikawa; Y. Hirose; K. Taguchi; K. Niimi; Y. Fujii; M. Usami; T. Kobayashi; S. Hamamoto; M. Hirose; Y. Itoh; T. Yasui; K. Tozawa; K. Kohri

Explore More

Collaboration

Dive into the Y. Fujii's collaboration.

Explore More
Researchain Logo
Decentralizing Knowledge